Company Profile
Emulate, Inc.
Company Overview
Our Human Emulation System sets a new standard for recreating true-to-life human biology and is being used to advance product innovation, design, and safety across a range of applications, including drug development, agriculture, cosmetics, food, and chemical-based consumer products.
We are continuously developing a wide range of Organ-Chips and disease models through collaborations with industry partners and internal R&D programs, and are also working with clinical partners to produce Organ-Chips personalized with individual patients’ stem cells, for applications in precision medicine and personalized health.
For more information, please visit: https://emulatebio.com
Company History
Our founding team pioneered the original Organs-on-Chips technology during their time working within the Wyss Institute for Biologically Inspired Engineering at Harvard University. We founded Emulate in July 2014 with a Series A investment led by the venture capital firm NanoDimension, alongside investment from Cedars-Sinai Medical Center and private investor Hansjörg Wyss. Emulate holds the worldwide exclusive license from Harvard University to a robust and broad intellectual property portfolio for the Organs-on-Chips technology and related systems.
Notable Accomplishments / Recognition
Collaborations with: NIH, AstraZeneca, Roche, Takeda, Merck, FDA, Janssen, DARPA, Seres Therapeutics, Wyss Institute, The Michael J. Fox Foundation, Covance, Cedars Sinai, USC
Benefits
A comprehensive benefits package that also includes: generous paid time off and holidays, 12 weeks parental leave, wellness initiatives, on-site workout space, work/life balance, parking and transportation, flexible work schedules, company events, dogs!!!